

CANCER

1

A COMPREHENSIVE TREATISE

ETIOLOGY: Chemical and Physical Carcinogenesis

CANCER 1

A COMPREHENSIVE TREATISE

ETIOLOGY: Chemical and Physical Carcinogenesis

FREDERICK F. BECKER, EDITOR

New York University School of Medicine

PLENUM PRESS • NEW YORK AND LONDON

Library of Congress Cataloging in Publication Data

Becker, Frederick F.

Etiology—chemical and physical carcinogenesis.

(His *Cancer, a comprehensive treatise*; v. 1)

Includes bibliographies and index.

1. Carcinogenesis. I. Title.

[DNLM: 1. Neoplasms. QZ200 B397c]

RC261.B42 vol. 1. [RC268.5] 616.9'94'008s

ISBN 0-306-35201-X

[616.9'94'071]

74-31195

© 1975 Plenum Press, New York

A Division of Plenum Publishing Corporation

227 West 17th Street, New York, N.Y. 10011

United Kingdom edition published by Plenum Press, London

A Division of Plenum Publishing Company, Ltd.

4a Lower John Street, London W1R 3PD, England

All rights reserved

No part of this book may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, microfilming, recording, or otherwise, without written permission from the Publisher

Printed in the United States of America

Contributors

to Volume 1

ROBERT W. BALDWIN, Cancer Research Campaign Laboratories, University of Nottingham, Nottingham, England

ISAAC BERENBLUM, The Weizmann Institute of Science, Rehovot, Israel

K. GERHARD BRAND, Department of Microbiology, University of Minnesota Medical School, Minneapolis, Minnesota

EMMANUEL FARBER, Fels Research Institute and Department of Pathology, Temple University School of Medicine, Philadelphia, Pennsylvania

JACOB FURTH, Institute of Cancer Research and Department of Pathology, Columbia University College of Physicians and Surgeons, New York, New York

W. E. HESTON, Laboratory of Biology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland

ALBRECHT M. KELLERER, Department of Radiology, Columbia University College of Physicians and Surgeons, New York, New York

ALFRED G. KNUDSON, JR., The University of Texas Health Science Center at Houston, Graduate School of Biomedical Sciences, Houston, Texas

CORNELIS J. M. MELIEF, Hematology Service, New England Medical Center Hospital, and the Department of Medicine, Tufts University School of Medicine, Boston, Massachusetts

PETER C. NOWELL, University of Pennsylvania, Philadelphia, Pennsylvania

MICHAEL POTTER, National Cancer Institute, Leukemia Studies Section, Bethesda, Maryland

MICHAEL R. PRICE, Cancer Research Campaign Laboratories, University of Nottingham, Nottingham, England

S. RAJALAKSHMI, Fels Research Institute and Department of Biochemistry, Temple University School of Medicine, Philadelphia, Pennsylvania

- viii** **JANARDAN REDDY**, Department of Pathology, University of Kansas Medical Center,
CONTRIBUTORS Kansas City, Kansas
- HARALD H. ROSSI**, Department of Radiology, Columbia University College of
Physicians and Surgeons, New York, New York
- D. S. R. SARMA**, Fels Research Institute and Department of Pathology, Temple
University School of Medicine, Philadelphia, Pennsylvania
- ROBERT S. SCHWARTZ**, Hematology Service, New England Medical Center Hospi-
tal, and the Department of Medicine, Tufts University School of Medicine,
Boston, Massachusetts
- JOHN B. STORER**, Biology Division, Oak Ridge National Laboratory, Oak Ridge,
Tennessee
- DONALD SVOBODA**, Department of Pathology, University of Kansas Medical
Center, Kansas City, Kansas
- GEORGE W. TEEBOR**, Department of Pathology, New York University School of
Medicine, New York, New York
- ARTHUR C. UPTON**, Health Sciences Center, State University of New York at Stony
Brook, Stony Brook, New York
- FREDERICK URBACH**, Temple University Health Sciences Center, Skin and Cancer
Hospital, Philadelphia, Pennsylvania
- J. H. WEISBURGER**, Naylor Dana Institute for Disease Prevention, American Health
Foundation, New York, New York
- G. M. WILLIAMS**, Fels Research Institute, Temple University School of Medicine,
Philadelphia, Pennsylvania

Preface

This series of books attempts to present, in a comprehensive manner, the field of oncology divided into three major areas; etiology, biology, and therapy. These books should serve as landmarks in the rapidly expanding experimental and clinical "universe" of this field. To some, they will be introductory; to others, a summary; for all, critical comments on the future of research. In recognition of the difficulties inherent in attempting to pause and reflect while experimental data emerge with ever-increasing rapidity, the presentations take the form of *overviews* rather than *reviews*. Where possible, an historical perspective on observations and experimentation which led to our present understanding is presented, the state of the art in technique and approach is reviewed, and the gaps in knowledge and in technique are indicated. The aim throughout is integration—using the findings from one approach for comparison with others.

The tremendous expansion of interest in oncology as a medical-biological discipline stimulated the publication of these volumes. This expansion, well warranted in terms of the impact of oncology on human morbidity, has been characterized by at least three phenomena. First, there has been an enormous increase in money and manpower devoted to the investigation and treatment of malignancy. That the research has become more and more "directed" or program-oriented signals the interest of those beyond the scientific community in the management of the effort. Second, increasing numbers of students are entering the field of oncology as their major training program. Third, public awareness of these activities has increased greatly, marked positively by large-scale support and negatively by hurried release of findings.

Nonetheless, one major problem continues to diminish the immediate importance of the results of every experiment and casts a shadow of doubt on the relevance of every observation. That problem is *our inability to define the malignant cell*. A vast amount of information exists that describes what this cell *does* and—to a lesser extent—*how* it does what it does; but the *why* evades us. Until now the malignant cell has been defined only in comparison with its normal version. We temporize, using the excuse that it is similar to its normal progenitor. Ultimately, our understanding of the malignant cell will rest on our ability to define the benign cell, within the study of cell biology. Once we acquire that knowledge, the

pattern of phenotypic schizophrenia which is typical of malignancy may assume real meaning. Until we grasp its definition, we will be able to describe the malignant cell only in the most general way, as a cell whose sense of order is defective—a cell which has lost its sense of belonging to a larger community. One might suggest then that the malignant cell is one which attempts to break free from its metazoan community and return to the primeval condition of individuality.

The impact of basic research on oncology has been particularly impressive in the recent search for the etiology of malignancy. Equally impressive is the contribution of clinical observation. For over a century, the association between exposure to specific substances or participation in particular occupations and an exceptional incidence of specific forms of tumors has been recognized. The epidemiological approach remains as pertinent today as ever in studying etiology, whether it relates to the ingestion of "natural" substances in the instance of hepatocarcinogenic aflatoxin or to the suspected relationship of vinyl chloride and malignancy. It is therefore in the study of etiology that the dual disciplines of laboratory investigation and clinical observation best demonstrate a harmony of effort.

The search for the effects of carcinogenic agents cannot be separated from the search for the etiology of malignancy. Without an appreciation of the nature of malignant development, we are helpless to define the key macromolecular events induced by such agents. We cannot differentiate between obligatory alterations and the broad spectrum of unrelated effects produced by oncogens. The strategy is clear: (1) We must identify carcinogenic agents, and by an analysis of their "nature," e.g., structure and physical characteristics, we may better understand their mechanism of action. (2) We must identify crucial interactions between these carcinogens and important macromolecules within the cell, distinguishing those which relate to carcinogenesis from those which are extraneous. (3) We must examine the alterations of cell function induced by these reactions, for it is with an understanding of phenotypic variation that we may know why malignant cells escape from normal homeostatic control. (4) Last, and perhaps of greatest importance, we must define malignancy—define those characteristics of cellular activity that permit the malignant cell to compete so effectively with the normal constituent, which ultimately leads to such destructive events.

The purpose of the first volume in this treatise is to present the progress that has been made toward these goals and to delineate the vast as yet unknown areas.

F.F.B.

New York

Contents

General Concepts

Cytogenetics

PETER C. NOWELL

1. Introduction	3
2. Human Leukemias	4
2.1. Chronic Granulocytic Leukemia and the Philadelphia-Chromosome	4
2.2. Other Myeloproliferative Disorders and "Preleukemia"	8
2.3. Acute Leukemias	10
2.4. Lymphoproliferative Disorders	12
3. Human Solid Tumors	14
3.1. Malignant Tumors	14
3.2. Benign and Precancerous Lesions	17
4. Animal Tumors	17
4.1. Viral Tumors and Transformed Cells	17
4.2. Solid Tumors and Clonal Evolution	19
5. Chromosome Breakage and Cancer	20
5.1. Genetic Disorders	21
5.2. Exogenous Agents—Radiation, Chemicals, Viruses	22
6. Conclusions and Speculations	24
7. References	28

Genetics: Animal Tumors

W. E. HESTON

1. Introduction	33
2. Speciation and Tumor Formation	34

xii	2.1. Invertebrates	34
CONTENTS	2.2. Vertebrates	36
	3. Hybridization and Tumor Formation	38
	3.1. Hybridization of Species	38
	3.2. Hybridization of Strains	39
	4. Inbreeding and Occurrence of Tumors	40
	4.1. Development of Inbred Strains	40
	4.2. Tumor Characteristics of Inbred Strains of Mice	41
	4.3. Role of Inbred Strains and Their Hybrids in Cancer Research	41
	5. Genetics of Spontaneous Tumors	42
	5.1. The Threshold Concept in the Inheritance of Cancer	42
	5.2. The Somatic Mutation Hypothesis	43
	6. Genetics of Chemically Induced Tumors	44
	6.1. Pulmonary Tumors in Mice	44
	6.2. Subcutaneous Sarcomas in Mice	45
	6.3. Selection of Appropriate Strain for Testing Carcinogens	45
	7. Genetics of Hormonally Induced Tumors	46
	7.1. Mammary Tumors	46
	7.2. Hypophyseal Tumors	47
	7.3. Adrenocortical Tumors	48
	8. Genetics of Virally Induced Tumors	49
	8.1. Inheritance of Susceptibility to the Mammary Tumor Virus	49
	8.2. Inheritance of Susceptibility to Leukemia	50
	8.3. Genetic Transmission of Tumor Viruses	50
	9. References	54

Genetic Influences in Human Tumors 3

ALFRED G. KNUDSON, JR.

1. Introduction	59
2. Genetic States Predisposing to Cancer	60
2.1. Chromosomal Disorders	60
2.2. Mendelian Conditions	61
3. Dominantly Inherited Tumors	63
3.1. Tumor Syndromes	63
3.2. Specific Tumors	65
4. A Mutation Model for Human Cancer	69
4.1. Initiation in Two or More Steps	69
4.2. Genetic Consequences	70
4.3. Role of Environmental Carcinogens	71
5. Conclusions	72
6. References	72

Hormones as Etiological Agents in Neoplasia

4

xiii
CONTENTS

JACOB FURTH

1. General Considerations	75
1.1. Historical	75
1.2. Nomenclature and Abbreviations	75
1.3. Neoplasia: Basic Defect and Types	77
1.4. Homeostasis (Cybernetics) and Neoplasia	80
1.5. Tumorigenesis by Hormonal Derangement	82
2. The Four Levels of Communications	85
2.1. Neurohypothalamic Areas and Neoplasia	85
2.2. Cell Type of the Adenohypophysis and Their Neoplasms	87
2.3. Neoplasia in Peripheral Endocrine-Related Organs	89
3. Detection of Hormonal Activity	94
3.1. General Considerations	94
3.2. Detection and Quantitation of Hormones	95
3.3. Steroid vs. Protein Hormones: Their Receptors and Translation of their Messages	96
4. Ectopic Hormones	102
5. Sequential Events: Multiglandular Syndromes	102
5.1. Neonatal Ovariectomy	103
5.2. Thyroidal Carcinogenesis	104
5.3. Multiglandular Diseases	106
6. Problems and Prospects	106
6.1. The Basic Change in Neoplasia	106
6.2. Carcinogenesis without Extrinsic Carcinogens	108
6.3. Relation of Neoplasia to Aging	111
6.4. Prospects	112
7. References	112

Immunocompetence and Malignancy

5

CORNELIS J. M. MELIEF AND ROBERT S. SCHWARTZ

1. Introduction	121
2. Deliberate Immunosuppression and Malignancy in Experimental Animals	123
2.1. Immunosuppression and Infection with Oncogenic Viruses	123
2.2. Effects of Immunosuppression on Oncogenesis by Chemicals	125
2.3. Effects of Immunosuppression on Development of Spontaneous Tumors	127
3. Spontaneous Immunosuppression and Malignancy in Experimental Animals	130
3.1. Congenitally Athymic (Nude) Mice	130

xiv	3.2. Immunocompetence of Animals with a High Incidence of Tumors	131
CONTENTS	3.3. Immunosuppression by Oncogenic Viruses	133
	3.4. Immunosuppression by Carcinogenic Chemicals	134
	4. Immunosuppression and Malignancy in Human Beings	135
	4.1. Immunodeficiency Diseases	135
	4.2. Neoplasms in Recipients of Organ Allografts	142
	5. Conclusions	146
	6. References	149

Pathogenesis of Plasmacytomas in Mice 6

MICHAEL POTTER

1. Introduction	161
2. "Spontaneous" Plasmacytomas	162
2.1. Ileocecal Plasmacytomas in Mice	162
2.2. Ileocecal Immunocytomas in Rats	162
2.3. Comment	163
3. Induced Plasmacytomas in Mice	164
3.1. Plasmacytomagenic Peritoneal Granuloma Inducing Agents	164
3.2. Genetic Basis of Susceptibility	167
3.3. The Peritoneal Site	168
3.4. Role of the Oil Granuloma	170
3.5. Role of Viruses in Plasmacytoma Development	172
4. Summary	179
5. References	179

Chemical Carcinogenesis

Metabolism of Chemical Carcinogens 7

J. H. WEISBURGER AND G. M. WILLIAMS

1. Cancer, a Class of Diseases Due Mainly to Environmental Factors: Synthetic or Naturally Occurring	185
2. Types of Chemical Carcinogens	186
3. Metabolism of Chemical Carcinogens	187
3.1. Direct-Acting Carcinogens	189
3.2. Procarcinogens	190

3.3. Specific Activation and Metabolic Systems	197	xv
4. Variation in Carcinogen Metabolism	214	CONTENTS
4.1. Species and Strain	215	
4.2. Sex and Endocrine Status	215	
4.3. Age	216	
5. Modification of Carcinogen Metabolism	217	
5.1. Diet	218	
5.2. Effect of Mode and Frequency of Exposure	218	
5.3. Effect of Other Agents	219	
5.4. Chemical Carcinogens and Mutagens	220	
6. Concluding Remarks and Prospects	221	
7. References	222	

Chemical Carcinogenesis: Interactions of Carcinogens with Nucleic Acids 8

D. S. R. SARMA, S. RAJALAKSHMI, AND EMMANUEL FARBER

1. Introduction	235
2. Interaction of Chemical Carcinogens with DNA	236
2.1. Covalent Interactions	236
2.2. Noncovalent Interactions	247
2.3. Purine- <i>N</i> -Oxides	249
2.4. Carcinogenic Metals	249
3. Interaction of Chemical Carcinogens with Mitochondrial DNA	249
4. Interaction of Chemical Carcinogens with RNA	250
4.1. General	250
4.2. Alkylating Agents	250
4.3. Aromatic Amines and Amides	254
4.4. Polycyclic Aromatic Hydrocarbons	255
4.5. 4-Nitroquinoline- <i>N</i> -Oxide	255
5. Influence of Carcinogen-Nucleic Acid Interactions on the Structure, Synthesis, and Function of DNA and RNA	255
5.1. Alterations in DNA Structure	255
5.2. Alterations in the Synthesis and Function of DNA and RNA	256
6. Carcinogen-DNA Interaction and Carcinogenesis	260
6.1. Carcinogen-DNA Interaction: Quantitative Analysis	261
6.2. Carcinogen-DNA Interaction: Qualitative Analysis	261
6.3. Repair <i>in Vivo</i> of DNA Damage Induced by Chemical Carcinogens	263
7. Perspectives and Conclusions	269
8. References	271

Some Effects of Chemical Carcinogens on Cell Organelles

9

DONALD SVOBODA AND JANARDAN REDDY

1. Introduction	289
2. The Carcinogens	290
2.1. Aflatoxins	303
2.2. Azo Dyes	305
2.3. Ethionine	306
2.4. Nitrosamines	309
2.5. Pyrrolizidine Alkaloids	311
2.6. Thioacetamide	312
3. Organelles	313
3.1. Endoplasmic Reticulum	314
3.2. Plasma Membrane	315
3.3. Mitochondria, Lysosomes, Microbodies	315
3.4. Nucleolus	317
4. Comment	318
5. References	319

Sequential Aspects of Chemical Carcinogenesis: Skin

10

ISAAC BERENBLUM

1. Origin of the Concept of Sequential Stages of Skin Carcinogenesis	323
2. The Search for Other Initiators and Promoters of Skin Carcinogenesis	324
3. Quantitative Analysis of the Two-Stage Mechanism	326
4. Critique of the Two-Stage Hypothesis	328
5. Extensions of the Two-Stage System	330
6. Factors Influencing Initiation and Promotion	331
7. Promoting Action in Other Tissues	334
8. The Mechanism of the Two-Stage Process	336
9. References	338

Sequential Aspects of Liver Carcinogenesis 11

GEORGE TEEBOR

1. Introduction	345
2. Attempts to Differentiate between Toxic and Premalignant Changes in Experimental Liver Carcinogenesis	346
3. Methods of Determining the Sequence of Events in Hepatocarcinogenesis	348
4. References	350

Neoantigen Expression in Chemical Carcinogenesis

12

xvii
CONTENTS

ROBERT W. BALDWIN AND MICHAEL R. PRICE

1. Introduction	353
2. Neoantigens on Chemically Induced Tumors	354
2.1. Tumor-Associated Neoantigens	354
2.2. Tumor-Associated Embryonic Antigens	367
2.3. Neoantigen Expression on Cells Transformed <i>in Vitro</i> by Chemical Carcinogens	373
3. Conclusions and Perspectives	375
4. References	377

Physical Carcinogenesis

Physical Carcinogenesis: Radiation—History and Sources

13

ARTHUR C. UPTON

1. Introduction	387
2. Types of Radiations	387
3. Sources and Levels of Radiation in the Environment	390
4. Historical Developments in Carcinogenesis by Ionizing Radiation	391
4.1. Observations in Humans	391
4.2. Observations in Experimental Animals	395
5. Evolution of Radiation Protection Standards	397
6. References	401

Biophysical Aspects of Radiation Carcinogenesis

14

ALBRECHT M. KELLERER AND HARALD H. ROSSI

1. Introduction	405
2. Interaction of Radiation and Matter	406
2.1. Mechanisms	406
2.2. Dosimetry	408
2.3. Microdosimetry	410
3. General Stochastic Considerations	414
3.1. The Linear Dose-Effect Relation at Small Doses	414
3.2. Dose-Effect Relation and the Number of Absorption Events	417

xviii	4. The Quadratic Dependence of the Cellular Effect on Specific Energy . . .	420
CONTENTS	4.1. Dose-Effect Relations	420
	4.2. Dose-RBE Relations	425
	5. Applications to Radiation Carcinogenesis	429
	5.1. Mammary Neoplasms in the Sprague-Dawley Rat	429
	5.2. Radiation Leukemogenesis	433
	6. Appendix	436
	7. References	437
	8. Selected General References	439

Ultraviolet Radiation: Interaction with Biological Molecules

15

FREDERICK URBACH

1. Introduction	441
2. Effects of Ultraviolet Radiation on Biological Systems	442
3. Photochemistry of Nucleic Acids	443
4. Photochemistry of Proteins	443
5. Photoinactivation of Cells and Tissues	444
6. DNA Repair	444
7. Enzyme-Catalyzed Photoreactivation	445
8. Excision Repair	446
9. Recombination Repair	447
10. Ultraviolet Light, DNA Repair, and Carcinogenesis	447
11. References	449

Radiation Carcinogenesis

16

JOHN B. STORER

1. Introduction	453
2. Tissue Sensitivity	454
2.1. Man	454
2.2. Experimental Animals	461
3. Dose-Response Relationships	462
3.1. Theoretical Considerations	462
3.2. Observed Dose-Response Relationships in Man	465
3.3. Observed Dose-Response Relationships in Experimental Animals	467
4. Threshold or Minimum Effective Doses	469
5. Physical Factors	470
5.1. Dose Rate	470

5.2. Radiation Quality	472	xix
5.3. Internal Emitters vs. External Exposure	473	CONTENTS
5.4. Total-Body Exposure vs. Partial-Body Exposure	473	
6. Host Factors	474	
7. Relationship to Spontaneous Incidence Rate	476	
8. Effect on Longevity	477	
9. Interactions with Other Agents	478	
10. Mechanisms	479	
11. References	479	

Foreign Body Induced Sarcomas 17

K. GERHARD BRAND

1. Introduction	485
2. Historical Background	485
3. Foreign Body-Associated Tumors in Man	486
4. Characteristics of Foreign Body Sarcomas	487
4.1. Histopathology	487
4.2. Ultrastructure	488
4.3. Growth Characteristics, Metastasibility, Transplantability	488
4.4. Antigenicity	488
4.5. Karyological Aberrations	489
5. Factors Determining Tumor Incidence and Latency	489
5.1. Genetic Background of Host Species	489
5.2. Genetic Background of Inbred Animal Strains	490
5.3. Influence of Sex	490
5.4. Histopathology of Foreign Body Reaction	490
5.5. Chemical and Physiochemical Properties of Foreign Bodies	493
5.6. Size and Shape of Foreign Bodies	493
5.7. Porosity of Foreign Bodies	494
5.8. Concluding Remark	494
6. Exploration of Preneoplastic Events in Foreign Body Tumorigenesis...	494
6.1. Histologically Suspected Preneoplastic Foci	494
6.2. Monoclonal Origin of Preneoplastic Cells	496
6.3. Appearance Time and Location of Preneoplastic Parent Cells and Clones in Relation to Foreign Body Reaction	496
6.4. Number of Preneoplastic Parent Cells Relative to Foreign Body Surface Area	497
6.5. Evidence for the Existence of Several Classes of Preneoplastic Cells According to Inherent Neoplastic Latency	497
6.6. Cell Type of Origin and Identification of Preneoplastic Parent Cells	497

XX	7. The Tumorigenic Process: Experimental Findings in Mice and Attempts at Interpretation	499
CONTENTS		
	7.1. Acquisition of a Specific Neoplastic Potential by "Parent Cells" During Early Foreign Body Reaction	499
	7.2. Neoplastic "Maturation" of Clonal Cells During the Latency Period	501
	7.3. Switch to Autonomous Tumor Growth	502
	8. Etiological Hypotheses of Foreign Body Tumorigenesis: A Critical Appraisal	502
	8.1. Chemical Components	502
	8.2. Physiochemical Surface Properties	503
	8.3. Interruption of Cellular Contact or Communication	503
	8.4. Tissue Anoxia and Insufficient Exchange of Metabolites	503
	8.5. Virus	504
	8.6. Disturbance of Cellular Growth Regulation	504
	9. References	505
	Index	513